Table 2

Clinical success rates by study population at the test-of-cure visit
Tigecycline CE population N = 209 (%) Comparator CE population N = 196 (%) Difference (Tigecycline vs Comparator)(95% CI)
Clinical diagnoses*
Deep soft tissue infections 114/150 (76.0) 103/132 (78.0) -2.0 (-12.6, 8.5)
Major abscess 30/36 (83.3) 34/43 (79.1) 4.3 (-15.5, 24.0)
Infected ulcers 17/22 (77.3) 15/20 (75.0) 2.3 (-28.3, 32.9)
Other populations
Diabetes mellitus 46/60 (76.7) 46/66 (69.7) 7.0 (-10.0, 24.0)
Peripheral vascular disease 20/27 (74.1) 16/20 (80.0) -5.9 (-34.4, 22.5)
Prior antibiotic failure 27/35 (77.1) 26/34 (76.5) 0.7 (-22.1, 23.5)

*Includes 2 CE patients with burns: 1 tigecycline cure and 1 comparator failure; Calculated using asymptomatic method corrected for continuity. CE, clinically evaluable; CI, confidence interval.

Matthews et al.

Matthews et al. BMC Infectious Diseases 2012 12:297   doi:10.1186/1471-2334-12-297

Open Data